# Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer

> **NCT00291486** · PHASE1 · COMPLETED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 19 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** 131I-huA33 (131-Iodine on humanised monoclonal antibody A33)

## Key facts

- **NCT ID:** NCT00291486
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2008-01-03
- **Final completion:** 2012-08-29
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2022-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00291486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00291486, "Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00291486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*